Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
This study has been completed.
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Francisco Robert,MD, University of Alabama at Birmingham
First received: March 5, 2009
Last updated: June 19, 2017
Last verified: June 2017
Small cell lung cancer, or SCLC, constitutes approximately 15% of the 170,000 new cases of lung cancer diagnosed annually in the United States. Extensive-stage SCLC comprises two thirds of new cases and is generally considered sensitive to chemotherapy, despite a median time to progression of 4 months. SCLC is one of the most aggressive and lethal types of cancer, with a median survival of 9 months (range 7-11 months) in patients diagnosed with extensive disease. Overall, the majority of patients with SCLC die in less than 2 years (2-year survival rates generally less than 10%), and the 5-year survival rate is 2.3% for patients with extensive disease. The regimen of etoposide in combination with a platinum (cisplatin or carboplatin) is generally considered the "standard of care" although a recent Phase III trial suggests improved survival with the combination of cisplatin/irinotecan. Further evaluation of new agents in combination regimens attempting to overcome the intrinsic drug resistance seen in extensive-stage SCLC is warranted attempting to improve survival and achieve palliation of disease-related symptoms.
Small Cell Lung Cancer
Extensive Stage Lung Cancer
Drug: Novel Drug Combination
||Intervention Model: Single Group Assignment
Intervention Model Description:
This is a single arm, open-label, Phase I - II trial with an initial dose escalation component and an expansion cohort of patients treated at the recommended Phase II dose.Masking: None (Open Label)
Primary Purpose: Treatment
||Phase I/IIa Study of the Novel Combination of Bendamustine With Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients With Extensive Stage Small Cell Lung Cancer
Primary Outcome Measures:
- Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I [ Time Frame: 9 weeks ]
The determination of the dose limiting toxicity as defined by The National Cancer Institute Common Toxicity Criteria version 3 as follows: grade 4 neutropenia >5 days; grade 3/4 febrile neutropenia; grade 4 thrombocytopenia; or grade >2 non-hematologic toxicities (except for nausea/vomiting, alopecia, or fatigue).
- Number of Patients With Adverse Events - Phase II [ Time Frame: 9 weeks ]
The degree of toxicity as defined by The National Cancer Institute Common Toxicity Criteria version 3.
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||May 2015 (Final data collection date for primary outcome measure)
Experimental: Novel Drug Combination
This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin.
This study has only one arm but it incorporates two phases. Phase I utilizes a combination of bendamustine and irinotecan for Regimen A followed by etoposide and carboplatin for Regimen B.
Drug: Novel Drug Combination
This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.
- All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.
- At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks.
- Irinotecan (Camptosar)
- Carboplatin (Paraplatin)
- Etoposide (VdPesid)
- Bendamustine (Treanda)
We are proposing a novel combination of bendamustine plus irinotecan followed by the standard regimen of etoposide with carboplatin. This will allow the investigation of response to the novel combination as well as any improvement in outcomes compared to historical controls.
|Ages Eligible for Study:
||18 Years to 79 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Histologic or cytologic diagnosis of extensive stage SCLC.
- Measurable or assessable tumor parameters.
- ECOG Performance Status 0-2.
- Age between 18 and 79 years (in the State of Alabama > 18).
- Adequate bone marrow, liver and renal function, defined as:
- Absolute neutrophil count (ANC) ≥ 1500/µL
- Hemoglobin ≥ 8g/dl
- Platelet count ≥ 100,000/µL
- SGOT/SGPT ≤ 2 x upper limit of normal or ≤ 5 x upper limit of normal when liver metastases are present.
- Total bilirubin value ≤ 2 x upper limit of normal.
- Serum creatinine value ≤ 2 x upper limit of normal.
- Fully recovered from any previous surgery (at least 4 weeks since major surgery)
- Must have recovered from prior radiation therapy (at least 3 weeks)
- All subjects must agree to practice approved methods of birth control (if applicable). A negative pregnancy test must be documented during the screening period for women of childbearing potential.
- Must provide written informed consent and authorization to use and disclose health information (HIPAA).
- Extensive-stage SCLC as defined as disease not confined to one hemithorax, including ipsilateral pleural effusion or pericardial effusion.
- No prior chemotherapy.
- Concurrent cancer chemotherapy, biologic therapy or radiotherapy.
- Administration of any investigational drug within 28 days prior to administration of the current therapy.
- Symptomatic brain metastases; those patients should be treated first with either whole brain radiation therapy or radiosurgery.
- Concurrent serious infection.
- Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor, which is likely to compromise patient safety and affect the outcome of the study.
- History of other malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for a minimum of 2 years.
- Neuropathy at baseline ≥ Grade 2.
- Any evidence or history of hypersensitivity or other contraindications for the drugs used in this trial.
- History of chronic diarrhea; or diarrhea (excess of 2-3 stools/day above normal frequency) in the past 2 weeks.
- History of a positive serology for human immunodeficiency virus (HIV).
- Psychiatric disorder that prevents patients from providing informed consent or following protocol instructions.
- Pregnant or lactating women.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00856830
|University of Alabama at Birmingham
|Birmingham, Alabama, United States, 35294 - 0104 |
|Georgia Cancer Specialists
|Marietta, Georgia, United States, 30060 |
University of Alabama at Birmingham
National Comprehensive Cancer Network
||Francisco Robert, M.D.
||University of Alabama at Birmingham
||Francisco Robert,MD, Professor, University of Alabama at Birmingham
History of Changes
|Other Study ID Numbers:
UAB 0818 ( Other Identifier: Institutional study protocol number )
|Study First Received:
||March 5, 2009
|Results First Received:
||March 3, 2017
||June 19, 2017
|Individual Participant Data (IPD) Sharing Statement:
|Plan to Share IPD:
Keywords provided by Francisco Robert,MD, University of Alabama at Birmingham:
Small cell lung cancer
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 23, 2017
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase II Inhibitors
Antineoplastic Agents, Alkylating